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Background: A high fat diet has an essential role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD).
This condition is characterized by hepatic fat accumulation (steatosis) and is associated with obesity, diabetes, and
fibrosis or cirrhosis of the liver. Probiotics may be useful in the treatment of steatosis. This study examined the
effects of an ingested probiotic formulation on the lipid profiles, liver functions, leptin levels, and inflammatory
marker levels of rats with NAFLD that had been induced via high fat and sucrose diet (HFSD).
Methods: Young male albino rats were randomly divided into three groups: a control group that was fed a
standard diet; a second group that was fed a HFSD; and a third group that was given both a HFSD and ingestible
probiotic mixtures. The groups were fed these diets for 16 weeks, and were then examined.
Results: HFSD-only rats showed hypertriglyceridemia, hypercholesterolemia, and elevated low density lipoprotein
(LDL) levels, and their serum alanine transaminase (ALT) and bilirubin levels were significantly higher than those of
the control group. Compared to rats on the standard diet, HFSD-only rats showed higher levels of tumor necrosis
factor alpha (TNF-α) and interleukin 6 (IL-6), increased serum leptin levels, and increased resistin hormone levels in
the adipose tissues. In the third group, the inclusion of the probiotic mixture seemed to ameliorate the effects of
the HFSD diet. The NAFD + probiotics group showed improved lipid profiles, better leptin and resistin levels, and
better TNF-α and IL-6 levels than the NAFD-only group. They also showed no signs of NAFLD.
Conclusions: The probiotic mixture showed promise as a treatment for NAFLD pathogenesis, and may improve
HFSD-induced steatosis through its effects on leptin, resistin, inflammatory biomarkers, and hepatic function
markers. We also established that gut microbiota-mediated regulation of lipid profiles was dependent on dietary
lipids and carbohydrates.
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The prevalence of non-alcoholic fatty liver disease
(NAFLD) has increased in several societies, and its treat-
ment and management have become economic and public
health priorities [1, 2]. A clear understanding of NAFLD,
and other manifestations of metabolic syndrome (MetS), is
required to develop effective therapies and improve exist-
ing ones [3]. Prevention and treatment of NAFLD are* Correspondence: kaothman@uod.edu.sa; kaamin10@yahoo.com
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to help people to avoid unhealthy diets, maintain healthy
lifestyles, and implement existing therapies using antioxi-
dants, oral hypoglycemics, and fat-lowering agents [4].
The intestinal epithelium is a mucosal barrier that is
part of our innate immune system, and it can release
proinflammatory cytokines such as interleukin 6 (IL-6)
and TNF-α In response to enteric pathogens [5]. The non
pathogenic bacteria that comprise the intestinal microflora
perform several functions that assist the host organism,
including the establishment of a protective barrier overle is distributed under the terms of the Creative Commons Attribution 4.0
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bolically and trophically. Therefore, any abnormality or
disruption in the microbiota (dysbiosis) may have deleteri-
ous consequences on the general health of the host [6].
The digestive tract harbors a microbiota that plays
vital roles in the onset and progress of health and dis-
ease [7, 8]. The internal environment of microbiota is
not inert, and can be influenced by dietary components
specially fat. Feeding an animal a high fat sucrose diet
(HFSD) resulted in obesity; this is a disease model that
we developed in previous work [9] and which is used to
imitate the obese phenotypes observed in the human
populations of Western and more developed societies.
HFD causes intestinal bacterial overgrowth and leads to
dysbiosis, which promotes endogenous signals that have
pathogenic roles in hepatic insulin resistance and hepatic
fat accumulation [10]. Previous studies have shown that
while a sucrose-rich diet does not necessarily result in
obesity, it can induce other issues: e.g., hypertrophy in
adipocytes, glucose intolerance, hyperinsulinemia, hyper-
lipidemia, and liver steatosis (a condition in which the
abnormal deposition of lipids inside a cell occurs) [11].
Thus, sucrose-rich diets can cause health problems and
have far-reaching, deleterious effects [12].
Gut bacterial metabolites with short chain fatty acids
(SCFAs), can affect host metabolism. Hippurate is con-
sidered a risk marker for diabetes, cardiovascular dis-
eases, and obesity, and acts as a signal for lipolysis and
food intake. Gut bacterial cellular components, such as
lipopolysaccharides (LPSs), flagella, structural lipids, and
peptidoglycans, can affect the host’s immune response,
induce insulin resistance, and cause MetS [13, 14].
Probiotics are live microorganisms that provide health
benefits to the host when ingested in appropriate
amounts [15]. A goal of probiotic use is the creation of
symbiotic relationships between the human host and
naturally occurring microorganisms, generating positive
effects on the human host’s overall health and ability to
resist illness [16]. Probiotics are safe and widely accepted
by the public. Over the past five years, they have devel-
oped into what is perceived as a natural treatment against
harmful factors associated with MetS and related disor-
ders [17–19]. Certain probiotics (Bifidobacterium or
Lactobacillus spp, Streptococcus thermophiles, and Akker-
mansia muciniphila) have been used to decrease obesity
and type 2 diabetes in HFD-fed model animals [20, 21].
Probiotics may attenuate MetS by modulating gut
microbiota, and have the capacity to modulate metabolic
phenotypes [19, 22, 23]. Consequently, there can be dif-
ferent probiotic effects on the gut microbiota compos-
ition, which can lead to distinct consequences and
improvements on the host’s metabolic health. However,
these processes are still poorly understood; this is prob-
ably due to insufficient steatosis models, insufficientdata, and the existence of contradictory data, that may
be resulted from low dose, short duration of administra-
tion. Some probiotics, including Bifidobacterium and
Lactobacillus, affect the cycle of the intestinal mucosa
barrier. Furthermore, certain probiotics types such as L.
acidophilus and L. rhamnosus can protect the mucosal
immune system by preventing the adhesion of harmful
bacteria to the gut endothelial lining, and by reducing el-
evated levels of fecal TNF-α [24].
The goal of this study was to investigate the effects of
probiotic ingestion on the lipid profiles and hepatic func-
tions of host animals, because of its accepting natural ther-
apies rather than taking pharmaceuticals and to answer
certain questions relating to the effects of gut bacteria. For
example, does the gut probiotics play a role in NAFLD
pathogenesis? What is the mechanism by which the gut
probiotics helps the host animal to maintain homeostasis?
The effects of probiotic ingestion on NAFLD and other
metabolic disorders have not yet been demonstrated, and
further research is needed to determine optimal probiotic
strains, algorithms of administration, and subsequent ef-
fects on organ functions. Probiotics appear to have great
potential in terms of benefiting human health, and this jus-
tifies the undertaking of additional research [25].
Some lactic acid bacteria (LAB) have been shown to
reside in the gastrointestinal tract (GIT) [24], with bene-
ficial functions that include cytokine regulation, main-
tenance of intestinal permeability, and control of the
immune response [26, 27]. However, the mechanisms
driving the immunological effects are not fully under-
stood. Based on previous work, we suggest that there is
poor communication between LAB, probiotics, and
immune cells; we also speculate that pro- and anti-
inflammatory mediators are regulated by probiotics and
have potential roles in the immune response [26, 27].
Bacterial surface proteins, metabolites, and secreted pro-
teins can stimulate cytokine secretion and can activate
NF-κB in cells in vitro [28]. However, the effects of these
bacterial products on host cytokine secretion and its
blood level require in vivo support and exploration to be
better understood; our study employs a mixture of bac-
teria at various concentrations, and laboratory rats as
the experimental in vivo components, to address this.
Our aim is to induce NAFLD disease in rats, using a
HFSD, to produce an animal model of human steatosis
in which we may monitor liver function biochemical
markers, lipid profiles, adiposity, and inflammation hor-
mone levels. We explore the subjects’ microbiota as af-
fected by the application of probiotics, and we propose
possible mechanisms for steatosis treatment via the ef-
fects of probiotics on disease markers. More specifically,
we focus on the use of a gut probiotics mixture and its
effects on the specific biomarkers related to hepatic stea-
tosis and its associated disorders.
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Diet
Two types of diet were used: 1) a control rat chow and
2) a HFSD (purchased from PE Enterprise, grain Riyadh
Branch, KSA, experimental animal feed #1005), . The
control rat chow consisted of protein concentrates
(350 g of soya bean, whey protein, and meat), corn
(600 g), calcium carbonate, dicalcium phosphate, sodium
chloride, magnesium oxide, and vitamins (50 g). This
standard or normal rat diet consisted of 65% carbohy-
drates (60% starch + 5% sucrose), 5% fat, 20% crude pro-
tein, 5% vitamins and minerals, and 5% dietary fiber.
The metabolic energy of this diet was 2813 kcal/kg, with
8% of this energy coming from fat. The HFSD was pre-
pared from protein concentrates (400 g), corn (350 g),
100% pure vegetable ghee (200 g at 9 kcal/g), and vita-
mins and minerals (50 g), according to the formulations
used by Amin et al. [9]. The HFSD consisted of 55%
carbohydrates, 20% fat (200 g SFA/kg food), 20% crude
protein, and 5% vitamins, minerals, and dietary fiber.
The metabolic energy of this diet was 5100 kcal/kg,
with 59% of this energy coming from fat. In addition,
sucrose (1 g/50 mL water) with high fat was used for
the induction of NAFLD in rats.
Experimental animals
Sixty, 6 week-old male rats were supplied by King
Abdulaziz City for Science and Technology (KACST),
with an average weight of 80–90 g. All rats were kept
under observation for one week upon arrival. All animals
were housed individually in plastic cages at 24 ± 3 °C, in
12 h light/12 h dark cycles, with humidity 40–60%, in the
laboratories of KACST, University of Dammam. Rats had
free access to water and diet.
Preparations for treatments
Probiotics
A commercially available probiotic described as a con-
centrated source of naturally occurring microorganisms
(AVI-5-BAC packet; Sure Pharmaceutical USA, Lombard,
IL, USA) was administered at a dose of 1 g per kg of food.
This probiotic mixture contained Lactobacillus acidoph-
ilus (10 × 108 CFU/g), Lactobacillus plantarum (9.8 ×
107 CFU/g), Bifidobacterium bifidum (2 × 106 CFU/g),
Bacillus subtilis fermentation extract (50 g per kg of prod-
uct), Aspergillus oryzae fermentation extract (50 g per kg
of product), and maltodextrin (added to 1 kg).
Chemicals
Sera were analyzed for total cholesterol (TC), triglycerides
(TGs), and high density lipoprotein (HDL) levels, LDL,
and bilirubin levels. These parameters determined colori-
metrically using kits purchased from Human Gesellschaft
fur Biochemica und Diagnostica mbH (Wiesbaden,Germany). Leptin and resistin were measured using an
ELISA kit from SPI Bio-Product PTY Ltd (# A051760
and # A05179) (Montigny le Bretonneux France). IL-6
and TNF-α ELISA detection kits were purchased from
Abcam (ab100712 and ab46105).
Experimental design and animal grouping
The experiments lasted 16 weeks and were divided in
two periods: 1) induction of steatosis (weeks 1–12), and
2) treatment (weeks 12–16). Sixty rats were used for this
study, and were randomized into three groups, each
group containing 20 rats. For the duration of the experi-
ment, body weights were recorded weekly; mean body
weights, and weight gains, were calculated.
Induction of hepatosteatosis
From weeks 1–12, the animals were divided into two
groups. The negative control group (20 rats) was fed the
standard rat chow diet for the duration of the experi-
ment (16 weeks), and the HFSD group (40 rats) was
maintained on the HFSD.
Probiotic treatment
From weeks 12–16 (the treatment phase), the HFSD group
(n = 40) was divided into two groups. Group 1 (n = 20) con-
tinued on the HFSD (positive control group), and group 2
received concomitant supplementation of probiotics at
doses of 1 g per 1 kg of HFSD (treatment group).
Blood and tissue sampling
Blood samples were collected from the medial canthus
of the eye, using a microhematocrit capillary tube, dur-
ing the fasting period. To collect the sera, blood samples
were collected in dry glass centrifuge tubes and were
allowed to clot at 24 ± 3 °C before being centrifuged at
1400 g for 20 min. The clear, non-hemolysed supernatant
sera were aspirated using clean, dry disposable plastic syrin-
ges, and were kept at −80 °C for subsequent biochemical
measurements. Upon completion of the experiment, rats
were sacrificed under anaesthesia, with blood and liver ex-
tracted for later analysis. Portions of the liver was fixed with
10% formalin for histopathological examination.
Biochemical analyses of serum and histopathological
examinations
Blood samples were used to carry out the biochemical
analysis of the lipid profiles, including TG, TC, LDL, and
HDL. We also tested for hepatic function by detecting
levels of alanine aminotransferase (ALT), bilirubin, and
albumin. Levels of the adipose tissue hormones leptin
and resistin, and of the cytokines TNF-α and IL-6, were
evaluated as inflammatory markers. Histopathological
examinations were also conducted using hematoxylin
and eosin (H&E) stain and examining tissues under the
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the presence or absence of inflammatory cells, the pres-
ence or absence of fat globules between and within the
hepatocytes, and any degenerative changes in hepatocytes.
Degrees of NAFLD were evaluated at low magnification
(4×, 10×) and higher magnification. Hepatocellular steato-
sis, fat globules, mild to moderate macro and microvesicu-
lar steatosis, inflammatory cells and lobular inflammation
were scored and the severity was graded [29]. Based on
the percentage of the total area affected, NAFLD cat-
egorized into score 0 (5%) considered normal, score 1
(5–33%) as mild, score 2 (33–66%) as moderate, and
score 3 (66%) as severe NAFLD.
Statistical analysis
Results are displayed as mean ± SEM, and were statisti-
cally analyzed using one-way analysis of variance
(ANOVA), followed by the Tukey-Kramer method for
post-hoc analysis. Values were considered significant
when p < 0.05; the different superscript letters (a, b, c)
indicate significant variations at P < 0.05 in the tables.
Statistical analyses were performed using the GraphPad
Prism 6 software application (San Diego, CA, USA).
Results
At baseline, there was no significant difference in body
mass between groups (p = 0.65). During the course of
the experiment, final and mean body weight gains indi-
cated significant increases in the HFSD group compared
with the normal or negative control group. Probiotic
treatment improved the final and mean body weight gain
values within the HFSD group (Table 1).
The groups displayed differences in sera lipid profiles.
The HFSD rats displayed significant increases in levels
of TG, TC (p < 0.001), and serum LDL (p < 0.01), while
also showing a significant decrease in levels of HDL (p <
0.01), compared to rats fed the normal diet (Table 2).
The group that was fed the probiotic mixture showed
significantly improved serum TG, TC, and LDL levels
compared to the group that was fed the HFSD only
(Table 2). There were also a significant increases in ALT
activity, and in total and direct bilirubin, in the HFSD
group compared to the normal group; this indicated the
deleterious impact of the HFSD on hepatocytes. The
group given the probiotic mixture displayed improved
levels of these hepatic markers when compared to theTable 1 Effects of normal diet and HFSD on body weight in rats
Normal
Initial body weight (g) 109.4 ± 4.52
Final Body weight gain 227.9 ± 15.36a
Mean body weight gain 60.03 ± 4.05a
These values represent means and standard errors, the different superscript lettersHFSD-only group (Table 3). Furthermore, the HFSD-fed
group showed significant increases in serum leptin and
resistin hormone levels compared to the group fed the
normal diet (Table 4); administering the probiotic mix-
ture appeared to regulate these hormonal imbalances.
Moreover, NAFLD in the HFSD-fed group resulted in
significant increases in IL-6 and TNF-α levels compared
to the groups fed the normal diet, while the group that
was given the probiotic mixture appeared to recover
from these changes.
A photograph showing high fat deposition around the
gut, and an enlarged liver, is presented in Fig. 1. This
also shows the proposed mechanisms of HFSD-induced
gut microbial alterations (via changes in levels of ROS,
IL-6, TNF-α, SCFA, and LPS), as well as overall meta-
bolic dysfunction and subsequent improvement via pro-
biotic administration. This figure indicates that changes
occurred in the gut microbiota and bile acid, due to the
HFSD. These changes resulted in elevations in free fatty
acid uptake and in the deposition of triglycerides, both
of which induced NAFLD, as indicated by levels of ROS
and inflammatory markers. Administration of probiotic
restore the normal microbiota therefore, improve NAFLD
via inhibition of lipogenesis and inflammatory markers.
The hepatic histopathological studies showed multiple
fat globules, mild to moderate macro and microvesicular
steatosis, degenerative changes, and focal periportal in-
flammation in the hepatic cells of the HFSD group
(Fig. 2a, b and c). By contrast, Fig. 2d reveals the normal
histological structure (non detectable macro and micro-
vesicular steatosis) that was typical of hepatic cells ob-
served in the normal-diet group. Figure 2e illustrates the
return of normal structure in the hepatic cells of the
probiotic-receiving group.
Concerning, NAFLD score, normal group had 0 score
for 90% of the cases and HFSD group revealed an in-
creases in the number of cases in the score 1 followed
by 2 (mild to moderate steatosis) while, probiotics group
presented increases in the number of cases in score 0
and 1, that indicate improve in the steatosis score
(Table 5).
Discussion
A mixture of probiotic strains was expected to have a
greater benefit on the health of the host than a single-
strain probiotic, due to their presumed synergistic effectsHFSD HFSD + Probiotic
101.6 ± 2.22 101.6 ± 2.22
268.7 ± 8.450b 238.7 ± 9.43a
71.78 ± 2.90b 64. 8 ± 3.80a
indicate significant variations at P > 0.05
Table 2 Effects of probiotics on lipid profiles in HFSD-fed rats
Normal HFSD HFSD + probiotics
TG (mg/dL) 111.03 ± 9.01a 229.33 ± 7.62b 203.0 ± 5.8c
TC (mg/dL) 78.08 ± 4.35a 110.6 ± 2.19b 98.02 ± 2.5c
LDL (mg/dL) 35.7 ± 2.33a 64.5 ± 6.59b 38.0 ± 2.26a
HDL (mg/dL) 88.99 ± 8.082a 37.79 ± 4.52b 51.28 ± 7.03b
Values represented as means and standard errors, the different superscript
letters describe a significant difference at P > 0.05
Table 4 Effects of probiotics on inflammatory markers and
hormone levels in HFSD-fed rats
Normal HFSD HFSD + probiotics
Leptin (pg/mL) 1525.2 ± 166.41a 2525.29 ± 153.7b 2105.0 ± 59.6c
Resistin (ng/mL) 2.75 ± 0.55a 5.71 ± 0.32b 3.09 ± 0.52a
IL6 (pg/mL) 0.095 ± 0.01a 0.270 ± 0.02b 0. 21 ± 0.016c
TNFα (pg/mL) 0.0089 ± 0.004a 0.04 ± 0.002b 0.012 ± 0.003c
Values represented as means and standard errors, the different superscript
letters mean a significant difference at P > 0.05
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host animals would presumably show diverse signs of
improved health and amelioration of metabolic syn-
dromes, in agreement with the findings of Yoo et al.
[20]. Our data indicated that the HFSD induced elevated
serum lipid profiles for TG, TC, and LDL, compared to
the normal diet (Table 2). These results agree with the
findings of Amin et al. [9]. The increased levels in the
lipid profiles may have been responsible for, or associ-
ated with, the accumulation of fat droplets observed in
the livers of HFSD-fed animals; this seemed to lead to
the development of various degrees of NAFLD, along
with macro, microvascular steatosis and focal periportal
inflammation (Fig. 2a, b and c).
Diets such as the HFD can induce changes in the con-
formation of gut microbiota which can increase gut per-
meability, reduce bacterial LPS removal, increase levels of
bacterial components, and induce metabolic endotoxemia.
Furthermore, this endotoxemia may result in subclinical
inflammation, leading to numerous metabolic dysfunc-
tions [7, 13, 30, 31], which can further result in distur-
bances in fat metabolism. These disturbances can be
indicated by increases in free fatty acid uptake, triglyceride
lipogenesis, and fat deposition in the hepatic tissues. This
condition may also lead to hepatosteatosis, with high
serum lipid profiles and increased lipogenesis.
Administration of the probiotic formulation appeared
to stabilize or reverse the increased values in lipid pro-
files, and stabilized or reversed the incidence of steatosis,
that had been observed in the HFSD groups. These
changes were associated with improvements in liver
function, serum TG levels, and leptin levels that control
fat metabolism during exposure to HFSD. AnotherTable 3 Effects of probiotics on liver function in HFSD fed rats
Normal HFSD HFSD + probiotics
ALT (U/L) 30.8 ± 1.94a 49.3 ± 4.39b 38.0 ± 2.79a
Albumin (g/dL) 3.13 ± 0.19a 3.00 ± 0.20a 3.08 ± 0.23a
T. proteins (g/dL) 8.41 ± 0.69 8.41 ± 0.56 7.88 ± 0.69
T. Bilirubin (mg/dL) 1.42 ± 0.16a 2.36 ± 0.23b 1.38 ± 0.18a
D. Bilirubin (mg/dL) 0.79 ± 0.09a 2.08 ± 0.1b 1.28 ± 0.16c
Values represented as means and standard errors, the different superscript
letters mean a significant difference at P > 0.05reason for observed improvements was the regulation of
the gut microbiota; in terms of quantity, a return to a
normal state was observed following the disturbances
that were noted as a result of exposure to the high fat
diet [9, 21].
Generally, the mechanism of probiotics effects may be
governed by three principles: 1) it benefits both the
host’s innate and acquired immunities, 2) it can restore
the gut microbiota equilibrium between pathogenic and
commensal bacteria, and 3) it can reduce the levels of
toxins generated from the either the host microbiota or
the food component [32]. A proposed mechanism for
HFSD-induced gut microbial alterations is via changes
in levels of ROS, IL-6, TNF-α, SCFA, and LPS, and their
associated metabolic dysfunctions and the improvements
generated by probiotics [5, 10] (Fig. 1). The normalizing
effects of probiotic administration on serum lipid pro-
files is through inhibition of lipogenesis. These findings
were consistent with those of Wu et al. [33], who found
that L. plantarum K21, as a probiotic, produced
cholesterol-lowering and bile salt-hydrolyzing capacities.
Serum leptin levels were significantly increased in the
HFSD group compared to the normal diet group, while
probiotic administration ameliorated this change. Leptin
is considered the major hormone in adipose tissues, and
its high levels explain the extraordinary amount of fatty
tissues observed in the livers and intestines of rats that
were fed the HFSD. Higher leptinemia may result in insulin
resistance, and may aggravate the conditions of NAFLD.
HFSD-induced elevations in serum resistin were due to in-
creased fat deposition in the hepatic tissues, while probiotic
administration resulted in decreases in serum resistin levels.
This may have been due to disruptions in hepatic fat depos-
ition, and improvements in hepatic steatosis. Resistin level
decreases within the probiotic-administered group may
have played an important role in reversing the accumula-
tion of hepatic fat; however, the molecular and biochemical
basis of the relationship between probiotics and resistin
levels has yet to be defined.
Probiotics facilitate the restoration of normal hormo-
nal activity in adipose tissues.
AST and ALT activity levels are the best clinical bio-
markers of hepatic functions and illnesses [34]. Rats fed
the HFSD showed alterations in ALT activity levels when
Fig. 1 Mechanisms of HFSD-induced gut microbial alterations (via ROS, IL-6, TNF-α, SCFA, and LPS) and metabolic dysfunctions, and subsequent
improvements mediated by probiotics
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was apparently a consequence of increased lipogenesis,
increased accumulation of lipids in the hepatic cells, and
increased focal periportal inflammation (Fig. 2a, b and c).
Additionally, enzymatic transaminases from cells are liber-
ated into the blood due to the damaging effects of the
presence of fat droplets, and also due to the elevated
amount of ROS generated from lipid peroxidation.
Our results were consistent with previous studies that
had indicated that R. verniciflua administration significantly
reduces ALT activity levels in carbon tetrachloride-treated
livers, and may be effective in reducing liver inflammation
[35]. Similarly, chronic alcohol consumption may produce
gut dysbiosis and may enhance the permeability of the in-
testines to endotoxins such as alcohol-generated acetalde-
hyde, which can interrupt constricted junctions. These
changes induce deteriorations in the intestinal microvilli,
but retreatment of mice with probiotics normalized the in-
testinal microvilli and restored connections [36, 37].
The present work showed that the HFSD induced in-
creases in markers of NAFLD, hypertriglyceridemia, and
hyperglycemia, and also generated deleteriously elevated
levels of liver function markers, final body weights, and
body weight gains, while the administration of a pro-
biotic mixture could counter these changes. Previous re-
searchers showed the effects of different probiotics on
the modulation of the gut bacterial structure and strain
composition when facing disturbances resulting from a
high dietary fat diet. HFD-induced metabolic syndrome
is due to structural disruptions of the intestinal micro-
biota, combined with inflammatory factors [38, 39].
Lactobacillus and Bifidobacterium, as probiotics,diminished body weight gain and macrophage penetra-
tion into epididymal fatty tissues, clearly enhanced
glucose-insulin homeostasis, and improved hepatic
steatosis (Fig. 2e). These bacteria shifted the overall
structure of the gut microbiota that had been dis-
turbed by the HFD towards that of lean mice fed a
normal diet [19]. This is consistent with the finding
that, overall, microbes may directly influence fatty
acid uptake and satiety responses either through regu-
lation of enteroendocrine cell numbers, or through
direct regulation of gut peptide hormone production
and secretion [40]. Our data revealed that TNF-α and
IL-6 levels in the serum of the HFSD group were sig-
nificantly increased, compared to those of the group
fed the normal diet (Table 4). However, when given
the probiotic mixture, the levels of these cytokines in
the HFSD group returned to normal.
Intestinal microorganisms affect cellular metabolism
in different hepatic and adipose tissues outside the gut;
in this way they can control the glucose and lipid
homeostasis, and the general inflammatory status, of
their host [17]. Ingestion of a high-fat diet produces
modifications within the intestinal microbiota and in-
creases gut-derived inflammatory agents by renewing
bowel flora in conditions of high fat diet-induced steato-
sis. However, the progress of inflammation is also an im-
portant factor, as it is associated with the appearance of
hyperphagia, obesity [38], and NAFLD, as a consequence
of changes in diet and microbiota.
The main type of fatty acid used in the HFSD of this
experiment was a long chain saturated palmitic acid.





Fig. 2 Histopathological results in the different groups of the experiment: a & b Microscopic analysis of the liver (H&E stain, magnification 20×)
showed multiple fat globules between and within hepatocytes, with concomitant degenerative changes in hepatic cells within the HFSD group.
Also NAFLD group revealed, macrovesicular steatosis (bold line arrow): major fat droplets are existing in hepatocytes; microvesicular steatosis
(dotted arrow): minor fat droplets are present in hepatocytes. c Liver focal periportal inflammation (magnification 40×) and aggregation (cluster) of
inflammatory cells (within dotted circles) in NAFLD group. d Typical histological structure of normal hepatic cells, with no inflammatory cells in the
perivenular area, within the normal group. e View of hepatic cells with normal shape and lower fat globules in the HFSD and probiotic mixture groups
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creased bacterial LPS amounts in the blood [39]. Stimu-
lation of fat cells with LPS, or with different kinds of
fatty acids (palmitic, myristic, or linoleic acids), has
shown that palmitic and stearic acids are capable of gen-
erating inflammation, either alone or synergistically with
LPS; however, these fatty acids combined with LPS in-
duce greater increases in IL-6 levels than does LPS alone
[41]. Fatty acids, either short or long chain, saturated or
unsaturated, can affect the stimulation of immunological
cells in the intestine, which in turn can produce variousTable 5 Histopathological features of normal, HFSD-fed rats and HF
Steatosis Score Normal (n = 20)
0 (<5%) 18 (90%)
1 (5–33%) 1 (5%)
2 (>33–66%) 1 (5%)
3 (>66%) 0 (0%)
0, 1, 2 and 3 indicate, steatosis score, while 5, 5–33,33–66 and 66% represent perceinflammatory reaction patterns [42, 43]. For example,
long-chain saturated fatty acids bind to toll-like receptor
4 (TLR-4) and induce pro-inflammatory cytokine ex-
pression in macrophages [44]. Increased production and
secretion of cytokines such as TNF-α and IL-6 may be
due to the incorporation of specific fatty acid types, such
as palmitic saturated long chain fatty acid, into the cell
membrane. This can alter the configuration of lipids
within the lipid bilayer, resulting in alterations or dis-
placements of biosignaling proteins from the lipid raft,
and modifying the stimulation of such receptor proteinsSD + Probiotic cases n (%)
HFSD (n = 20) HFSD + Probiotic (n = 20)
0 (0%) 11 (55%)
12 (60%) 7 (35%)
7 (35%) 2 (10%)
1 (5%) 0 (0%)
ntage of the total area affected in the examined slides
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mation [41]; therefore, although soft butter may posi-
tively disturb normal blood lipids (lipemia), the high
amount of SFA may activate inflammation independently
from LPS action. Indeed, the long chain saturated pal-
mitic and stearic fatty acids that were used in the HFSD
of this study are able to trigger the release of inflamma-
tory biomarkers such as IL-6 and TNF-α.
Overgrowth, strain specificity, and/or low microbiota
richness inside the small intestine may stimulate the in-
ternal formation of ethanol, lead to choline insufficiency,
and increase bacterial LPS. These factors are involved in
the process of intestinal barrier damage, which may en-
hance the regular interactions between gut microbiota
and may increase the occurrence of some products and
hepatic receptors, such as TLR. This process may result
in stimulating a cascade of actions leading to NAFLD,
resulting in inflammation and hepatic cirrhosis [46].
These effects are indicated by the elevation of lipid pro-
files and inflammatory markers in blood serum.
In summary, HFSD, fatty acid type, hyperleptinemia,
microbiota overgrowth (and its consequent metabolites),
and LPS, were able to enhance the production of the in-
flammatory biomarkers IL-6 and TNF-α; this induced
and aggravated hepatosteatosis, thus allowing for pro-
gression toward different degrees of fibrosis in the ex-
perimental animals. These results agree with those of
Hong et al. [47], who reported that probiotics down-
regulated the alcohol-induced expression of TLR-4 in
animals fed normal diets and HFD. Additionally,
alcohol-induced liver diseases could be effectively treated
using probiotics to regulate the gut-liver axis. Using a
cocktail of probiotics, we found that Bifidobacterium
and Lactobacillus strains affected host inflammation,
adipose tissue hormone levels, and intestinal microbial
composition. Treatment of HFSD-induced NAFLD with
different probiotic mixtures induced modifications
within the intestinal microbiota that attenuated meta-
bolic disruptions by reducing serum lipid profiles and in-
flammatory biomarkers. Our work provides novel data
suggesting that multistrain probiotics, composed of a
mixture of Lactobacillus plantarum, Bifidobacterium,
and Bacillus subtilis strains, would be effective in treat-
ing NAFLD.
Conclusions
In conclusion, the probiotic formula used in this study
was effective in the treatment of NAFLD by ameliorating
increased lipid profiles, liver function markers, inflam-
matory markers, and leptin and resistin hormone levels.
Probiotics constitute potential therapeutic and nutri-
tional treatments that allow the control of hepatosteato-
sis and associated disorders. There are links between the
gut-liver axis, fat metabolism, hormonal balances withinadipose tissues, and inflammatory mediators that results
in hepatic steatosis and associated disorders. Understand-
ing these links, and the different mechanisms that are in-
volved, requires further investigation. Future studies that
search for the best probiotic strains, doses, and algorithms
of administration are needed. Probiotic administration
shows great potential as a treatment for hepatic diseases;
this justifies more research in the future. Further studies
in humans are also needed.
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